Breadcrumb Home Studies Studies Search Filter Research Area All Brain and Mental Health Cure and Immunotherapy Therapeutics Tuberculosis Study Status All Closed to Accrual Closed to Follow Up Concluded Enrolling In Development Participants Off Study and Primary Analysis Completed Pending Sort Study Number Asc Study Number Desc Submit Search Showing 6 studies. IMPAACT 2053: Long-Acting Injectable Cabotegravir as Postnatal Prophylaxis During Breastfeeding: Safety, Tolerability, and Model Development for Implementation DAIDS Number 39282 Research Area Therapeutics Study Status In Development IMPAACT 2050: CREATE DAIDS Number 39208 Research Area Therapeutics Study Status Enrolling IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Enrolling IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Enrolling IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
IMPAACT 2053: Long-Acting Injectable Cabotegravir as Postnatal Prophylaxis During Breastfeeding: Safety, Tolerability, and Model Development for Implementation DAIDS Number 39282 Research Area Therapeutics Study Status In Development
IMPAACT 2047: Radiant-Moms Plus DAIDS Number 39188 Research Area Tuberculosis Study Status In Development
IMPAACT 2041: Phase I/II Study of the Pharmacokinetics and Safety of Glecaprevir/Pibrentasvir Initiated in Pregnancy in Women with Hepatitis C with and without HIV DAIDS Number 39052 Research Area Therapeutics Study Status Enrolling
IMPAACT 2024 : Phase I/II Dose Finding, Safety and Tolerability Study of Daily Rifapentine Combined with Isoniazid (1HP) for Tuberculosis Prevention in Children Less Than 13 Years of Age with and without HIV. DAIDS Number 38747 Research Area Tuberculosis Study Status Enrolling
IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1 DAIDS Number 38637 Research Area Therapeutics Study Status Participants Off Study and Primary Analysis Completed
